OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kozuch on the Role of ctDNA Following Surgery in CRC

August 24th 2022

Peter Kozuch, MD, discusses the role of circulating tumor DNA in colorectal cancer.

Dr. O’Shaughnessy on Pembrolizumab in Triple-Negative Breast Cancer

August 23rd 2022

Joyce A. O’Shaughnessy, MD, discusses the sequencing of pembrolizumab with chemotherapy in patients with early-stage triple-negative breast cancer.

Women in Oncology: Resilience That Leads to Innovation

August 23rd 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss how they turned their leukemia career “lemons” into “lemonade.”

Dr. Beckermann on the Evolving Adjuvant Setting in RCC

August 22nd 2022

Kathryn E. Beckermann, MD, PhD, discusses the evolving adjuvant treatment setting for renal cell carcinoma.

Dr. Mato on Factors for Choosing BTK Inhibitors or Venetoclax in CLL

August 22nd 2022

Anthony Mato, MD, MSCE, discusses the factors used to make treatment decisions between BTK inhibitors and venetoclax in chronic lymphocytic leukemia.

Dr. Garcia on the Role of Ruxolitinib in Myelofibrosis

August 22nd 2022

Jacqueline S. Garcia, MD, discusses the role of ruxolitinib (Jakafi) in myelofibrosis.

Dr. Levy on the Approval of Trastuzumab Deruxtecan in HER2-Mutant NSCLC

August 19th 2022

Benjamin Levy, MD, discusses the significance of the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Dr. Choueiri on the Future Examination of Adjuvant Pembrolizumab in RCC

August 19th 2022

Toni Choueiri, MD, discusses the future examination of adjuvant pembrolizumab in renal cell carcinoma.

Dr. Nassif on Examining Gut Microbial Signatures in the Tumor Microenvironment

August 19th 2022

Elise Nassif, MD, discusses examining gut microbial signatures in the tumor microenvironment.

Dr. Long on Evaluating Adjuvant Pembrolizumab vs Placebo in Melanoma

August 19th 2022

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses evaluating pembrolizumab vs placebo in stage IIB or IIC melanoma.

Women in Oncology: Bringing Advances From the Lab Into the Clinic

August 19th 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss what motivated them to continue working toward improvements in the leukemia field, even when outcomes were dismal and treatment options were scarce.

Dr. Zhen on Future Research Efforts in Neuroendocrine Carcinomas

August 18th 2022

David Zhen, MD, discusses future research efforts in poorly differentiated small cell neuroendocrine carcinomas.

Dr. Goldkorn on the Methods Used to Predict Chemotherapy Benefit in Bladder Cancer

August 18th 2022

Amir Goldkorn, MD, discusses the methods utilized to predict chemotherapy benefit in bladder cancer.

Dr. Bhatt on the Longitudinal Effects of Chronic Diseases in Childhood Cancer Survivors

August 18th 2022

Neel S. Bhatt, MBBS, MPH, discusses the longitudinal effects of chronic diseases in childhood cancer survivors.

Women in Oncology: How Early Treatments Paved the Way for Future Advances

August 18th 2022

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss the challenges that accompanied the lack of progress in leukemia treatment when they began their fellowships and express their excitement about encouraging developments that have since emerged in the arena.

Dr. Ip on Next-Generation Sequencing in Myeloid Neoplasms

August 17th 2022

Andrew Ip, MD, discusses the use of targeted next-generation sequencing in detecting chromosomal structural abnormalities in patients with myeloid neoplasms.

Dr. Usmani on the Rapidly Evolving Landscape in Multiple Myeloma

August 17th 2022

Saad Z. Usmani, MD, MBA, FACP, discusses the rapidly evolving treatment landscape in multiple myeloma.

Dr. Lin on Patient Eligibility for CAR T-cell Therapy in Hematologic Caners

August 17th 2022

Yi Lin, MD, PhD, discusses patient eligibility for CAR T-cell therapy in hematologic cancers.

Dr. Florez (Duma) on Nihilism in SCLC

August 17th 2022

Narjust Florez (Duma), MD, discusses nihilism in small cell lung cancer.

Dr. Ahn on Choosing Between Treatment Options in CLL

August 16th 2022

Inhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.